The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.
The grant will allow Weill Cornell to study genetic, social, and clinical factors that might explain why COVID-19 disproportionally affects minorities in the US.
The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
At Scientific American, a trio calls on community leaders, scientists, and others to prevent increased racial and economic disparities in science due to pandemic-related school closures.
The company is commercializing a genome-wide sequencing method called MRDetect, developed by researchers at the New York Genome Center and Weill Cornell Medicine.
In Phase 2 pilots, four healthcare organizations helped HL7 refine its FHIR Genomics specification but uncovered many remaining hurdles to true interoperability.
The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
Researchers at Mount Sinai, NYU School of Medicine, and Weill Cornell Medicine sequenced hundreds of SARS-CoV-2 genomes from NYC patients for phylogenetic analyses.
